Patents Examined by John Doll
  • Patent number: 5023281
    Abstract: Provided are microbiocidal solutions comprising an aryl alkanol solvent and a microbiocidal compound dissolved therein. The solutions may be used to impart microbiocidal properties to polymer compositions.
    Type: Grant
    Filed: July 20, 1989
    Date of Patent: June 11, 1991
    Assignee: Morton International, Inc.
    Inventors: Nuno M. Rei, Ronald C. Wilson
  • Patent number: 5023322
    Abstract: The invention relates to new peptides of the formula ##STR1## wherein R.sup.2 represents Ala or D-Ala,R.sup.11 represents Arg or D-Arg,R.sup.13 represents Val or Ile,R.sup.15 represents Gly, Leu, Phe or a valence bond,R.sup.27 represents Met or Nle,R.sup.28 represents Ser, D-Ser or Asn, andY represents OH or NH.sub.2,and to salts thereof. These compounds stimulate the release of growth hormone and can be used in the therapy as well as for veterinary or animal husbandry purposes.
    Type: Grant
    Filed: August 30, 1989
    Date of Patent: June 11, 1991
    Assignee: MTA Kutatas-es Szervezetelemzo Intezete
    Inventors: Magdolna Kovacs, Judit Horvath, Sandor Vigh, Imre Mezo, Istvan Teplan, Balazs Szoke, Janos Seprodi, Zsolt Vadasz, Edit Hegedus, Gabor Makara, Gyorgy Rappay
  • Patent number: 5021551
    Abstract: A method is disclosed for enhancement of the immunogenicity of a T cell immunogenic peptide which comprises adding an acidic amino acid at the N-terminus and/or a positive charge at the C-terminus of said peptide.
    Type: Grant
    Filed: January 18, 1989
    Date of Patent: June 4, 1991
    Assignee: Washington University
    Inventors: Paul M. Allen, Emil R. Unanue
  • Patent number: 5021237
    Abstract: A gel insecticide bait to be contained in a pressurized container, for dispensing a bead of gel bait in cracks, crevices and the like for destroying insects, in particular cockroaches, said composition comprising an oil-in-water emulsion of a pentadienone toxicant-fatty acid mixture in a corn syrup solution, together with a gellant.
    Type: Grant
    Filed: November 27, 1989
    Date of Patent: June 4, 1991
    Assignee: The Clorox Company
    Inventor: Francis J. Bruey
  • Patent number: 5019384
    Abstract: Novel methods or compositions are provided for modulating the immune system, so as to be able to selectively stimulate or inactivate lymphocytes in relation to a particular transplantation antigen content. Particularly, mixtures may be employed associated with the more common transplanatation antigens of a host population. In this manner, a large number of people can be treated, for example, by immunization, stimulation of particular T-cells or B-cells in relation to a pathogenic invasion of other aberrant state, e.g. neoplasia, treatment of autoimmune diseases, and the like. Particularly, the compositions may involve an oligopeptide involving as a first region a consensus sequence and an epitope or the first region may be joined to a second region comprising an antibody target sequence which is capable of competing with an epitopic site of an antigen of interest.
    Type: Grant
    Filed: November 13, 1989
    Date of Patent: May 28, 1991
    Assignee: Massachusetts Institute of Technology
    Inventors: Malcolm L. Gefter, Jean G. Guillet
  • Patent number: 5017690
    Abstract: N-formyl amino acid or peptide is deformylated by reaction with aniline or methylene dianiline over noble metal catalyst, e.g., Pt-on-carbon. N-formanilide is formed as by-product. The process is particularly useful in deformylating N-formyl aspartame.
    Type: Grant
    Filed: August 11, 1989
    Date of Patent: May 21, 1991
    Assignee: W. R. Grace & Co.-Conn.
    Inventor: Jennifer M. Quirk
  • Patent number: 5017688
    Abstract: This invention relates to peptides involved in the pathogenesis of human immunodeficiency virus ("HIV"). More particularly, this invention relates to peptides from the env region of the HIV genome and the use of such peptides in methods and compositions for preventing, treating, or detecting acquired immune deficiency syndrome ("AIDS") infection.
    Type: Grant
    Filed: October 30, 1989
    Date of Patent: May 21, 1991
    Assignee: Biogen, Inc.
    Inventors: Walter Gilbert, Richard A. Fisher, Vicki L. Sato, Kuzhalmannam L. Ramachandran
  • Patent number: 5017346
    Abstract: A process of refining zinc oxide from roasted zinc sulphide bearing concentrates comprises leaching the concentrate in an aqueous sulphur dioxide solution under controlled conditions providing selective separation of zinc from other elements contained in the concentrate. The zinc bisulphite solution so obtained is separated from the remaining solids and is heat treated, preferably with steam, to precipitate zinc monosulphite crystals, possibly after first adding zinc dust to the solution to cement out residual copper and cadmium. The zinc monosulphite is then separated from the solution, possibly washed with water, and calcined to yield purified zinc oxide.
    Type: Grant
    Filed: May 11, 1988
    Date of Patent: May 21, 1991
    Assignee: Ecolomics Inc.
    Inventors: Donald R. Spink, Murry C. Robinson, Kim D. Nguyen
  • Patent number: 5015729
    Abstract: A dimeric protein with inhibin activity is isolated from ram reta testis fluid using reverse-phase high-performance liquid chromatography and gel filtration. The isolated molecule is composed of two chains having apparent molecular weights of about 18,000 and about 16,500 to 14,500 Daltons, as measured by gel electrophoresis, which are bound together by disulfide bonding and the longer of which is likely glycosylated. Microsequencing revealed the NH.sub.2 -terminal portion of the longer chain to be Ser- Thr-Pro-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Gln-Arg-Pro-Pr o- Glu-Glu-Pro-Ala-Ala-His-Ala-Asp-Cys and of the shorther chain to by Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe. This dimeric protein specifically inhibits basal secretion of FSH, but not of LH, in a rat anterior pituitary monolayer culture system, exhibiting a half-maximal effective dose of about 0.1 to 0.3 ng/ml.
    Type: Grant
    Filed: June 23, 1988
    Date of Patent: May 14, 1991
    Assignee: The Salk Institute for Biological Studies
    Inventors: Joachim Spiess, Jean E. F. Rivier, C. Wayne Bardin, Wylie W. Vale, Jr.
  • Patent number: 5013722
    Abstract: Cholecystokinin analogs useful for suppressing food intake in mammals and humans.
    Type: Grant
    Filed: August 25, 1989
    Date of Patent: May 7, 1991
    Assignee: Hoffmann-LaRoche Inc.
    Inventors: Waleed Danho, Vincent S. Madison, Joseph Triscari
  • Patent number: 5013546
    Abstract: Methods and compositions are described for increasing and decreasing immunoglobulin production by administering to a human or other mammalian subject an appropriate dosage of amplifier. Administration of amplifier to subjects having excessive production of immunoglobulin, namely AIDS and ARC patients, is shown as decreasing such excessive immunoglobulin production in such patients.
    Type: Grant
    Filed: March 29, 1990
    Date of Patent: May 7, 1991
    Assignee: Imreg, Inc.
    Inventors: A. Arthur Gottlieb, Robert C. Sizemore
  • Patent number: 5013719
    Abstract: This invention relates to a method of effecting immunosuppression in a patient in need thereof, comprising co-administering to said patient an effective amount of an immunosuppressive agent, wherein said immunosuppressive agent is not an ornithine decarboxylase inhibitor, and an effective amount of an ornithine decarboxylase inhibitor.
    Type: Grant
    Filed: May 13, 1988
    Date of Patent: May 7, 1991
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventor: Terry L. Bowlin
  • Patent number: 5013550
    Abstract: Novel compounds, called chloropolysporins B and C, and salts thereof have antibiotic properties and would appear to be members of the class of glycopeptide antibiotics containing chlorine. They may be produced by cultivating a suitable strain of microorganism of the genus Micropolyspora, especially Micropolyspora sp. SANK 60983 (FERM BP-538). They may be combined with conventional pharmaceutically acceptable carriers or diluents for therapeutic use or incorporated into edible excipients, such as feed or water, for use as a growth-promoting agent, especially for farm animals.
    Type: Grant
    Filed: February 6, 1990
    Date of Patent: May 7, 1991
    Assignee: Sankyo Company Limited
    Inventors: Tatsuo Haneishi, Takao Okazaki, Akio Torikata, Mutsuo Nakajima
  • Patent number: 5011686
    Abstract: Disclosed is a method of targeting reagents to the locus of a clot, and a family of substances that have affinity for fibrin. The method and substances exploit the discovery that the binding sites on protein A from Staphylococcus aureus have a significant affinity for fibrin. These fragments, analogs thereof, and oligomers of the fragments or analogs, may be attached to fibrinolytic enzymes, remotely detectable radiation emitting moieties, or healing agents to produce reagents which have affinity for the site of a wound or intravascular clot where fibrin has been deposited. Constructs comprising repeats of truncated analogs of the binding domain have low affinity for circulating immunoglobulin and high affinity for fibrin.
    Type: Grant
    Filed: November 15, 1989
    Date of Patent: April 30, 1991
    Assignee: Creative Biomolecules, Inc.
    Inventor: Roy H. L. Pang
  • Patent number: 5011591
    Abstract: New crystalline titanium molecular sieve zeolite compositions having a pore size of about 8 Angstrom Units are disclosed together with methods for preparing the same and organic compound conversions.
    Type: Grant
    Filed: June 5, 1989
    Date of Patent: April 30, 1991
    Assignee: Engelhard Corporation
    Inventor: Steven M. Kuznicki
  • Patent number: 5009865
    Abstract: A crystalline bar is drawn by a zone-melting process or from a melt in a crucible utilizing a magnetic suspension housing, in addition to an axial stabilization magnet, a radial stabilizer surrounding the core and including sensors for the radial position of the core-operating controllers for electromagnets surrounding the core to restore the core to its setpoint position. The fully magnetic suspension of the core eliminates friction while allowing enclosure of the crystal growth compartment to improve the quality of the crystal growth process.
    Type: Grant
    Filed: September 4, 1985
    Date of Patent: April 23, 1991
    Assignee: Kernforschungsanlage Julich GmbH
    Inventors: Karl Boden, Harald Ibach, Udo Linke
  • Patent number: 5008241
    Abstract: Insulin analogs characterized by amino acid residue at A21 other than Asn, with a resulting improvement in stability of insulin solutions at acid pH levels. Some insulin analogs may also have amino acid residue changes elsewhere so that these insulin analogs exhibit at least about one charge more than human insulin at a pH value of 7, with preferred substitutions being made for the glutamic acid residues at A4, A17, B13, B21 and/or a basic amino acid residue being substituted at B27. Also contemplated is optional blocking the C-terminal carboxyl group of the B-chain with an amido or ester residue.
    Type: Grant
    Filed: October 20, 1989
    Date of Patent: April 16, 1991
    Assignee: Novo Nordisk A/S
    Inventors: Jan Markussen, Kjeld Norris, Liselotte Langkjaer
  • Patent number: 5004519
    Abstract: The disclosure relates to a radiation heat shield which is formed of graphite which covers the open end of the crucible of a furnace for forming single crystals of silicon by the Czochralski method. The graphite preferably has a silicon carbide coating thereon. The heat shield is preferably formed in plural segments with a counterweight at one end of each of the segments whereby, upon raising of the crucible, the segments and associated counterweight rotate about a pivot to expose the top of the crucible.
    Type: Grant
    Filed: September 12, 1988
    Date of Patent: April 2, 1991
    Assignee: Texas Instruments Incorporated
    Inventor: Farouk A. Hariri
  • Patent number: 5002931
    Abstract: The invention provides synthetic peptides which are extremely potent in stimulating the release of pituitary GH in animals, including humans, which have resistance to enzymatic degradation in the body, and which have the sequence: (B)R.sub.1 -R.sub.2 -R.sub.3 -Ala-Ile-Phe-Thr-R.sub.8 -Ser-(Q.sub.1)R.sub.10 - Arg-R.sub.12. (Q.sub.2)R.sub.13 -Leu-R.sub.15 -Gln-Leu-Ser-(Q.sub.3)Ala-Arg. R.sub.21 -(Q.sub.4)R.sub.22 -Leu-Gln-Asp-Ile-R.sub.27 -R.sub.28 -Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-R.sub.42 -R.sub.43 -R.sub.44 wherein R.sub.1 is Tyr, D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, His or D-His; B is H, C.sup.a Me, N.sup.a Me, desamino, Ac or For; R.sub.2 is Ala, D-Ala, NMA or D-NMA; R.sub.3 is Asp or D-Asp; R.sub.8 is Ser, Asn, Lys, Arg, Asp or Gln; R.sub.10 is Tyr, D-Tyr or Phe; R.sub.12 is Arg or Lys; R.sub.13 is Ile, Val, Leu or Ala; R.sub.15 is Gly or Ala; R.sub.21 is Lys, D-Lys or D-Arg; R.sub.22 is Leu, Ile, Ala or Val; R.sub.27 is Met, D-Met, Ala, Nle, Ile, Leu, Nva or Val; R.sub.
    Type: Grant
    Filed: May 22, 1987
    Date of Patent: March 26, 1991
    Assignee: The Salk Institute for Biological Studies
    Inventors: Jean E. F. Rivier, Wylie W. Vale, Jr., Catherine L. Rivier
  • Patent number: 5003043
    Abstract: The present invention discloses synthetic peptides and antibodies raised thereto wherein the synthetic peptides represent important epitopic sites recognized by the 0.5 .alpha. antibody, a human monoclonal antibody which can neutralize HTLV-I. Also, the uses of these peptides or antibodies thereto either alone or in combination with peptides representing the epitopic site for the predominant antibodies found in HTLV-I env seropositive sera as diagnostics, therapeutics and vaccines are disclosed.
    Type: Grant
    Filed: May 25, 1988
    Date of Patent: March 26, 1991
    Assignee: Triton Biosciences Inc.
    Inventors: Robert W. Akita, Dagne L. Florine, John S. Ralston